Table 1. Baseline characteristics of the study cohort.

	Total	ε2/ε2	ε2/ε3	ε2/ε4	ε3/ε3	ε3/ε4	ε4/ε4	p value
Number (%)	3,844	22 (0.6)	491 (12.8)	99 (2.6)	2,371 (61.7)	810 (21.1)	51 (1.3)
Age, years	72 ± 5	74 ± 6	73 ± 6	73 ± 5	73 ± 5	72 ± 5	72 ± 5	0.069
Female	60	73	62	65	60	60	59	0.743
BMI (kg/m2)	26.3 ± 4.5	26.3 ± 3.8	26.6 ± 4.4	26.0 ± 3.9	26.5 ± 4.5	25.9 ± 4.4	25.8 ± 5.0	0.021
Smoking								p = 0.542
Never	1,775 (46)	11 (50)	226 (46)	50 (51)	1,106 (47)	356 (44)	26 (51)
Former	1,633 (43)	7 (32)	204 (42)	44 (44)	997 (42)	360 (45)	21 (41)
Current	436 (11)	4 (18)	61 (12)	5 (5)	268 (11)	94 (12)	4 (8)
Diabetes	14	14	13	11	15	12	4	0.030
Hypertension	56	68	55	57	57	54	59	0.831
Systolic BP (mmHg)	135 ± 21	141 ± 23	136 ± 20	135 ± 18	135 ± 22	135 ± 21	140 ± 22	0.325
Total cholesterol (mg/dl)	213 ± 39	173 ± 38	200 ± 37	202 ± 38	213 ± 39	218 ± 39	232 ± 45	< 0.001
LDL cholesterol (mg/dl)	131 ± 36	83 ± 27	116 ± 32	120 ± 32	132 ± 35	137 ± 35	144 ± 42	< 0.001
HDL Cholesterol (mg/dl)	54 ± 16	54 ± 14	55 ± 16	52 ± 14	54 ± 16	54 ± 16	57 ± 19	0.250
Triglycerides (IQR)	125 (95, 169)	126 (103, 190)	131 (97, 180)	129 (88, 213)	122 (94, 165)	124 (97, 166)	140 (100,199)	0.058
Lipid lowering medications	6	5	5	2	5	7	12	0.063
eGFRcreat (ml/min/1.73 m2)	72 ± 17	71 ± 15	72 ± 18	74 ± 16	72 ± 17	73 ± 17	75 ± 17	0.324
eGFRcys (ml/min/1.73 m2)	70 ± 17	66 ± 10	69 ± 17	71 ± 17	69 ± 17	70 ± 17	74 ± 18	0.187
CKD eGFR < 60 (ml/min/1.73 m2)
eGFRcreat	25	23	26	22	26	22	18	0.165
eGFRcys	27	27	28	23	28	24	20	0.094

Values expressed as mean ± standard deviation (SD) for continuous data and percentages for dichotomous data.